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Abstract
Introduction: By rising diabetes mellitus prevalence, the prevalence of its most complication; cardiovascular
disease (CVD) is also increasing. Moreover, oxidative stress has important role in pathogenesis of diabetes and
its complications. We investigated relationship between total antioxidant status (TAS) and surrogate measures
of subclinical atherosclerosis (SA) with glycemic status in diabetics.
Methods & materials: In a cross-sectional study, we recorded height, weight, waist circumference (WC) and
blood pressure of 267 subjects. Blood samples were collected to measure fasting blood sugar (FBS), glycated
hemoglobin (HbA1c), lipid profiles and TAS. The surrogate measures of SA were Carotid Intima Media
Thickness (CIMT), and Ankle Brachial Index (ABI).
Results: We found significantly lower TAS leves and ABI values and higher CIMT in diabetic patients
especially in poor glycemic group. There was a nonsignificant, weak correlation between TAS, ABI and CIMT
with glycemic status (r = −0.10, −0.16, and +0.09, respectively). Multivariate regression analysis showed a
significant influence of increasing age and diabetes duration on worsening CIMT in poor glycemic group.
Conclusions: Our study showed poor glycemic control leads to worse CIMT by increasing age and duration
of diabetes. However we did not find a significan correlation between glycemic status and TAS levels. We
suggest CIMT measurement along with other SA markers in poor glycemic diabetics, especially in older
patients with longer duration of diabetes, to identify high risk CVD patients.
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Background
Diabetes mellitus is a chronic hyperglycemic state asso-
ciated with serious cardiometabolic abnormalities such
as insulin resistance, hyperlipidemia, hypertension, and
obesity. These aberrancies are almost always accompan-
ied by oxidative stress [1]. A significant reduction in the
efficiency of antioxidant defenses and/or overproduction
of reactive oxygen species (ROS) [2] has a crucial role in
the development of the diabetes complications [2]. In
diabetic patients, oxidative stress is evident within a few
years after involvement and before complications be-
come manifest [3].
Cardiovascular disease (CVD) is the most threatening
complication of diabetes. While the leading cause of
mortality worldwide, it is three to four times more com-
mon in diabetics than non-diabetics individuals [4, 5].
On the other hand it is established that the diabetes itself
is an independent risk factor for accelerating of athero-
sclerosis. The role of hyperglycemia as an independent
risk factor for development of CVD is supported by the
United Kingdom Prospective Diabetes Study (UKPDS) [6].
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As the prevalence of DM is rising, it will be a major con-
tributory risk factor of increased CVD events. Like other
developing countries we are confronting an escalating
trend of CVD in Iran [7]. So measurement of surrogate
markers of atherosclerosis is of utmost importance for
circumventing CVD end-points, especially in diabetics
subjects. A reliable measure of metabolic control in dia-
betics is glycosylated hemoglobin (HbA1c) which reflects
recent mean glucose concentration over the past 3 months
and provides a relatively substantial base for prediction of
CVD events [8, 9]. It is expected that improving glycemic
control with HbA1c would delay the onset and ameliorate
the severity of diabetic complications [6].
It is possible to evaluate plasma markers of oxidative
stress. One of oxidative stress indicators is total antioxi-
dant status (TAS) which represents the plasma level of
cumulative antioxidant reserve of the body and enables
the evaluation of the average antioxidant potential [10].
Conflicting reports on serum concentration of TAS in
patients with CVD have been reported in epidemio-
logical studies [11]. However, given its feasibility, meas-
urement of TAS can be used as a valuable tool for
investigating the association between dietary antioxidant
status and CVD [12].
Atherosclerosis is the most common type of CVD.
There are several non invasive methods to assess sub-
clinical atherosclerosis (SA) including Carotid Intima
Media Thickness (CIMT) [13], and Ankle Brachial Index
(ABI) [14]. CIMT is a valid surrogate marker of CVD
that can detect intimal atherosclerotic process and med-
ial hypertrophy in carotid arteries. Increased CIMT is an
early phenomenon in development of atherosclerosis
even in asymptomatic individuals [13].
It is established both asymptomatic and symptomatic
PAD can increase the risk of CVD. Ankle brachial index
(ABI) is a simple, inexpensive, and noninvasive measure
and also sensitive and cost-effective screening tool for
peripheral artery disease (PAD) [15]. ABI can also pro-
vide useful information about cardiovascular health both
in general population and in clinical settings [15].
There are various reports about the effect of glycemic
control on CVD risk reduction in type 2 diabetes melli-
tus (T2DM) [16, 17]. However, we didn’t find any study
to assess the association between glycemic status with
oxidative stress and surrogate measures of CVD in
T2DM. This cross-sectional study was designed to deter-
mine the effect of metabolic control on plasma status of




We conducted a cross-sectional study in 267 partici-
pants; 150 non-diabetics and 117 T2DM patients
during a period of 12 months between January 1th and
December 31th2012 in diabetes clinic of Dr. Shariati
Hospital, Tehran/ Iran. T2DM was diagnosed accord-
ing to American Diabetes Association criteria [9]. In-
clusion criteria were T2DM or non-diabetics aged
between 35–75 years (mean ± SD 51.5 ± 8.1 years).
Subjects who ingested antioxidant supplements and
drugs in last 3 months ago, suffering from acute or
chronic inflammatory/ infectious conditions, past
medical record of CVD or acute myocardial infarction,
and chronic diseases such as chronic renal failure, or
cirrhosis were excluded from the study. After obtain-
ing the written consent of participants, T2DM patients
were divided into two groups of good control
(HbA1c ≤ 7.5 %) and poor control (HbA1c > 7.5 %) ac-
cording to their glycemic status.
A personal and demographic questionnaire was filled
for all of the patients. Height, weight, waist circumfer-
ence (WC) and blood pressure were measured with
standard tools and recorded. Body mass index (BMI)
was calculated by deviding weight (kg) to height squared
(m)2. WC was measured on broadest area between the
edge of lower ribs and the iliac crest in standing pos-
ition. Systolic and diastolic blood pressures were mea-
sured after 5–10 min rest, on the right arm in sitting
position. Hypertension was defined as systolic blood
pressure/ diastolic blood pressure ≥ 140/90 mmHg or
under treatment with antihypertensive medications.
Laboratory measures
Blood samples were collected in fasting state and were
analyzed for fasting blood sugar (FBS), total choles-
terol (TC), triglycerides (TG) and high density
lipoprotein cholesterol (HDL-C) by autoanalyser, Pars
Azmoon Kit (Iran). The low density lipoprotein
cholesterol (LDL-C) was derived by Fredrickson-
Friedwald’s formula [LDL-C = (TC– HDL-C)– TG/5],
if TG level was < 400 mg/dl [18]. Dyslipidemia was defined
as TC ≥ 200, TG ≥ 150 mg/dl, LDL-C > 100 mg/dl,
HDL-C < 40 mg/dl in men and < 50 mg/dl in women
based on definition of dyslipidemia in NCEP ATP III1
[19] or taking anti-hyperlipidemic medications. HbA1c
was measured by DS5 chromatography; Drew Scientific
Limited Company (UK). TAS levels were measured by
ELISA kits [Cayman (US)].
Subclinical atherosclerosis measures
We measured CIMT and ABI for detection of subclinical
atherosclerosis. Ultrasonographic analysis of the carotid
arteries was performed with a high-resolution ultra-
sound scanner, equipped with a linear array 13 MHz
transducer (MyLab 70 X vision, biosound esaote USA).
For detection of CIMT special software (vascular tools 5,
Medical Imaging Applications LLC, USA) was employed.
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The means of the three maximum right and three max-
imum left far wall measurements of the proximal part,
mid part and the bulb were calculated for each common
carotid artery. In our study, all the six right and left wall
values were measured and the average values noted. The
cut off point for SA definition by CIMT was considered
an extreme increase of common carotid IMT ≥ 0.8 mm
[20]. ABI was measured as the ratio of the average
systolic blood pressure at the ankle of each leg divided
by the average systolic blood pressure in the arm. Then
the highest blood pressure of limbs considered. The
ABI ≤ 0.9 was considered diagnostic for PAD [15].
This study was approved by the Ethics Committee of
Tehran University of Medical Sciences of Tehran/ Iran.
Statistical analysis
The normal distribution of data was verified by
Kolmogrov-Smirnov analytic test. All variables had
normal distribution except TG, TAS, and CIMT.
Paired T-Test was applied to variables with normal
distribution, and Wilcoxon and Mann–Whitney non-
parametric tests for analysis of following parameters:
TG, TAS, and CIMT. Also, we used univariate and
multivariate logistic regression models according to
HbA1c categorized status (<7.5/ ≥7.5 %) adjusted for
sex, age, duration of diabetes, BMI, WC, hyperten-
sion, and hyperlipidemia. Outcome variables included
plasma levels of TAS, and surrogate measures of SA,
that were CIMT and ABI. All independent variables
which had p < 0.2 in the univariate model were se-
lected for the multivariate analysis. The p value ≤ 0.05
was considered as statistically significant.
Results
The baseline characteristics of all participants are shown
in Table 1.
Of our diabetic patients, 7 patients (6 %) were on diet-
ary restriction alone, while 14 (12 %) and 21 (17.9 %)
were taking metformin or glibenclamide, respectively. 62
patients (53 %) were under treatment with combination
of metformin and glibenclamide, and 13 subjects
(11.1 %) were on combination therapy with metformin
and insulin. Mean ± Standard deviation (SD) of diabetes
duration was 8.9 ± 6.6 years. The number of smokers,
hypertensive and hyperlipidemic subjects in diabetes
group were 10 (8.5 %), 60 (51.3 %) and 108 numbers
(92.3 %), respectively.
The baseline characteristics of diabetic patients accord-
ing to glycemic status are shown in Table 2. The poor con-
trol group were dominantly women, had higher levels of
FBS, TC, TG, LDL-C, HbA1c, CIMT, WC, BMI and lon-
ger duration of diabetes with lower TAS levels and ABI
compared to the good control group (Table 2).
In diabetes group, TAS was similar in males and females
(mean 3.14 mmol/l in men vs. 3.11 mmol/l in women.
Inter-quartile range of TAS that determines difference
between quartiles 75 and 25 was also similar in men
[3.23–2.86 mmol/l] and women [3.16–2.80 mmol/l]; (p =
0.79). In addition TAS levels decreased with age in men
(3.17 vs. 3.13) and increased in females (3.10 vs 3.12) but
without significant differences;(p = 0.82, and p = 0.93,
respectively).
The correlation between indices of glycemic status and
TAS was a weak negative correlation (r = −0.10) with
nonsignificant statistical difference (p = 0.30). This cor-
relation for CIMT, and ABI was r = 0.09, and r = −0.16,
respectively. The difference in all of these correlations
was not statistically significant, p = 0.30, and p = 0.09, re-
spectively. Coefficients of univariate and multivariate re-
gression models between TAS, CIMT, and ABI as
outcomes with demographic characteristics, BMI, WC,
hypertension, and hyperlipidemia as covariates according
to glycemic status (≤7.5/>7.5) are shown in Table 3.
Discussion
We found significantly lower TAS leves and ABI values
in diabetic patients. In addition CIMT was significantly







Age (year) 49.8 ± 7.5 53.8 ± 8.3 <0.001*
Female (n (%)) 87 (58) 61 (52.1) 0.38
Diabetes duration (year) ———— 8.9 ± 6.6 ———
SBP (mmHg) 126 ± 17 134 ± 18 <0.001*
DBP (mmHg) 78 ± 11 78 ± 10 0.93
BMI (kg/m2) 28.4 ± 4.3 28 ± 4.3 0.41
WC (cm) 92 ± 10.7 94.8 ± 10.8 0.04*
TC (mg/dl) 200 ± 34 176 ± 42 <0.001*
TG (mg/dl)a 161 ± 80 193 ± 109 0.002*
LDL-C (mg/dl) 114 ± 23 95 ± 26 <0.001*
HDL-C (mg/dl) 46 ± 10 42 ± 9 <0.001*
FBS (mg/dl) 95 ± 12 166 ± 63 <0.001*
HbA1c (%) 5.3 ± 0.6 8 ± 1.8 <0.001*
TAS (mmol/l)a 3.2 ± 0.8 3.1 ± 0.6 0.02*
Max. CIMT (mm)a 1 ± 0.5 1.3 ± 1 <0.001*
ABI 1.17 ± 0.11 1.13 ± 0.11 0.003*
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass
index, WC waist circumference, TC total cholesterol, TG triglycerides, LDL-C low
density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, FBS
fasting blood sugar, HbA1c glycated hemoglobin A1c, TAS total antioxidant
status, Max. CIMT maximum carotid intima media thickness, ABI ankle
brachial index
*P ≤ 0.05 was considered as statistically significant
aFor variables with abnormal distribution nonparametric analytic tests
were used
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higher in diabetics compared to the control group. After
dividing diabetics into two subgroups according to the
glycemic status, we did not find any significant influence
of glycemic status on TAS and ABI. However, glycemic
status showed a significant influence on the association
between age and diabetes duration with CIMT. By in-
creasing age and duration of diabetes, accretion of
CIMT was significantly more in poor glycemic group
versus well controlled diabetics.
The excess risk for CVD mortality in diabetics can be
justified to some extent by increased prevalence of trad-
itional risk factors such as hypertension, obesity and
hyperlipidemia in this group [21]. For example, the re-
sults of the United Kingdom Prospective Diabetes
Study (UKPDS) showed a significant association be-
tween increased risk of CVD in diabetics with hyperlip-
idemia and increased HbA1c levels [22]. However, an
important contributory factor for excess risk of CVD in
diabetes would be oxidative stress which is associated
with increased lipid peroxidation [2]. Hyperglycemia
associated with hyperlipidemia is a causative factor for
increased lipid peroxidation in diabetics [23]. This is
supported by impaired antioxidant status and increased
oxidative damage to lipids in type 2 diabetes. In this
regard use of antioxidant nutrients is suggested as adju-
vants in the prevention of CVD in T2DM [24]. All of
the different parameters of hyperglycemia, acute or
chronic, contribute to the vascular damage, likely via
generation of reactive oxygen species. We observed sig-
nificantly higher levels of dyslipidemia parameters in
our poor glycemic group than those with good glycemic
control. This is a substantial finding as the results of
UKPDS have proven that good control of diabetes cor-
rects lipid abnormalities in almost 65 % of these sub-
jects [25]. So, strict glycemic control should be the first
objective to prevent CVD associated with oxidative
damage to lipids in T2DM.
Of various markers for oxidative stress detection in
diabetes, total Antioxidant Status (TAS) considers the
cumulative action of all the antioxidants present in
Table 2 Baseline characteristics of 117 diabetic patients








Age (year) 54.3 ± 8 53 ± 8.5 0.50
Female (n (%)) 26 (42.6) 35 (57.4) 0.58
Diabetes duration (year) 6.9 ± 5 10 ± 6.5 0.004*
SBP (mmHg) 133 ± 19 135 ± 17 0.44
DBP (mmHg) 77 ± 11 79 ± 9 0.20
BMI (kg/m2) 27.7 ± 4 28 ± 4 0.58
WC (cm) 94.8 ± 9 94.7 ± 12 0.92
TC (mg/dl) 166 ± 32 184 ± 47 0.02*
TG (mg/dl)a 174 ± 97 211 ± 115 0.02*
LDL-C (mg/dl) 89 ± 21 101 ± 28 0.01*
HDL-C (mg/dl) 42 ± 9 41 ± 10 0.72
FBS (mg/dl) 126 ± 27 199 ± 65 <0.001*
HbA1c (%) 6.5 ± 0.7 9.3 ± 1.3 <0.001*
TAS (mmol/l)a 3.23 ± 0.68 3.04 ± 0.52 0.30
Max. CIMT (mm)a 1.25 ± 0.83 1.41 ± 1.08 0.30
ABI 1.16 ± 0.11 1.11 ± 0.11 0.03*
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass
index, WC waist circumference, TC total cholesterol, TG triglycerides, LDL-C low
density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, FBS
fasting blood sugar, HbA1c glycated hemoglobin A1c, TAS total antioxidant
status, CIMT carotid intima media thickness, ABI ankle brachial index
*P ≤ 0.05 was considered as statistically significant
aFor variables with abnormal distribution was used nonparametric
analytic tests
Table 3 Associatieon between diabetic control (HbA1c) with surrogated markers of subclinical atherosclerosis and total antioxidant
score in Univariate and multivariable logistic regression models
Independent
variables
CIMT (≤0.8 / >0.8) ABI (≤0.9 / >0.9) TAS (≤ Median / > Median)
Univariate odds
ratio CI 95 %
Multivariate odds
ratio CI 95 %
Univariate odds
ratio CI 95 %
Multivariate odds
ratio CI 95 %
Univariate odds
ratio CI 95 %
Multivariate odds
ratio CI 95 %
HbA1c % 1.12 (0.90 – 1.40) 1.17 (0.87 – 1.56) 1.18 (0.88 – 1.58) 1.16 (0.87 – 1.55) 0.94 (0.72 – 1.22) 0.89 (0.67 – 1.17)
Age (year) 1.09 (1.03 – 1.15) 1.10 (1.03 – 1.18) 0.98 (0.92 – 1.05) - 1.01 (0.96 – 1.07) -
Sex (F/M) 0.83 (0.37 – 1.84) - 0.42 (0.13 – 1.31) 0.51 (0.15 – 1.72) 0.68 (0.28 – 1.66) -
Diabetes duration
(year)
1.06 (0.99 – 1.13) 0.98 (0.91 – 1.07) 0.99 (0.90 – 1.08) - 0.98 (0.92 – 1.06) -
BMI (kg/m2) 0.92 (0.83 – 1.02) 1.00 (0.83 – 1.20) 0.89 (0.77 – 1.03) 0.92 (0.80 – 1.07) 1.01 (0.90 – 1.12) -
WC (cm) 0.94 (0.90 – 0.99) 0.91 (0.83 – 0.99) 0.98 (0.94 – 1.03) - 1.03 (0.98 – 1.08) -
Hypertension
(Y/N)
2.87 (1.24 – 6.60) 4.20 (1.41 – 12.51) 1.53 (0.51 – 4.62) - 1.40 (0.57 – 3.42) -
High LDL-C (Y/N) 3.94 (1.19 – 13.01) 3.77 (0.84 – 16.86) 0.47 (0.06 – 3.86) - 2.86 (0.79 – 10.30) 3.26 (0.86 – 12.33)
CIMT carotid intima media tickness, ABI ankle brachial index, TAS total antioxidant status, BMI body mass index, WC waist circumference, Hypertension high blood
pressure ≥140/90 mmHg or histoey of hypertension, High LDL-C LDL-C ≥ 130 mg/dl
The variables with P< 0.2 in univarIable models enter in multivariable models
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plasma and body fluids; and provides an integrated
measure of oxidative stress rather than simply asses-
sing sum antioxidants [26]. It is proven that measure-
ment of TAS is of paramount importance in diagnosis
of oxidative state [26]. In addition TAS is a useful
marker to determine prognosis and guide antioxidant
therapy [26].
The level of TAS in the poor glycemic group in our
study, was lower than the well controlled glycemic
ones; although with a non- significant statistical differ-
ence, which was in agreement with previous reports
[27]. In a study by Willems et al. in type 1 diabetic
patients, there was no difference in TAS levels between
the 2 subgroups with and without subclinical complica-
tions; however both of these subgroups were glycemi-
cally well controlled [28].
We suggest that the association of low TAS levels
with poor glycemic status would justify prescription of
antioxidant supplies as dietary supplements in the
treatment of poor glycemic diabetics. Moreover, hyper-
tension and hyperlipidemia which very often coexist
with type 2 diabetes produce oxidative stress and con-
tribute to low TAS levels in these patients [29, 30].
While antioxidant therapy is advantageous in secondary
prevention of oxidative damage, it laso assists in con-
trol of hypertension and dyslipidemia [31]. Antioxidant
therapy also hinders progression of vascular damage in
diabetics by helping optimal control of glucose in these
patients [31].
An interesting finding of this study was an age
dependent increase in TAS among women who were
metabolically controlled; although this favourable effect
was not observed in men.
Sundaram et al. have demonstrated an age-dependent
reduction in total antioxidant capacity, and an age inde-
pendent increase in lipid profile and oxidative damage in
elderly diabetics [32]. In the elderly diabetics, age-related
perturbations of TAS would contribute significantly to
the development of cardiovascular complications. This
idea is worth to be testified in complementary larger
scale trials.
The association between increased CIMT and CVD
is well established [33]. CIMT is increased in patients
with T2DM [34]. In the Epidemiology of Diabetes
Interventions and Complications (EDIC) study, CIMT
was measured 18 months after the Diabetes Control
and Complications Trial (DCCT) and the investigators
did not find a significant correlation between mean
levels of HbA1c with CIMT during the study period.
However when this measurement was extended 6 years
later, a significant positive association was observed in
both sexes between mean HbA1c levels and CIMT
[35]. After 18 years, this association was still consist-
ent and also more robust in diabetic women. This
may be related to stronger atherosclerotic effect of
CVD risk factors in women compared to men.
There are various reports in the literature regarding
the association of CIMT with risk factors of carotid ath-
erosclerosis. Some authors [36, 37] were unable to find a
statistically significant correlation between CIMT and
CVD risk factors in diabetic patients. Other investigators
nonetheless, have reported a significant association be-
tween CIMT and age, sex, smoking, blood pressure,
body mass index [38–40] and the presence of diabetes
or glucose intolerance [34, 41, 42]. In our study, like the
findings of two other research groups [36, 37], we did
not observe a significant correlation between CIMT and
gender, hyperlipidemia, hypertension, obesity, or HbA1c.
However, we found just a significant association between
age and duration of diabetes in poor glycemic group. It
is probably because diabetes itself is of crucial import-
ance for the development of atherosclerosis because of
clustering of multiple interrelated metabolic distur-
bances over- shadowing the contribution of other risk
factors.
Peripheral Artery Disease (PAD), a manifestation of
atherosclerosis in the lower limbs occurs with more than
four-folds increased risk in diabetics. With each 1 % in-
crease in HbA1c, the risk of PAD increases 28 %. Cur-
rently the most widely accepted test to assess PAD is the
ABI. Decreased ABI is a major risk factor of CVD mor-
tality [43] and low ABI (≤0.9) is an indicator of PAD
[15]. These observations in diabetics may simply reflect
the severity of diabetes due to its long duration and poor
glycemic control. In general, risk factors for PAD are
similar to those of coronary artery disease [44, 45].
There are diverse findings regarding the effect of gly-
cemic control on PAD in T2DM. Some studies show a
significant associatin between fasting serum glucose and
HbA1c with PAD; in contrast to others [46, 47].
Although, there is no conclusive evidence to suggest
that optimal glycemic control lowers the risk of PAD, in
the presence of an increased risk of cardiovascular
events, it is logical that optimal glycemic control would
be desirable in patients with PAD. In our patients, there
was no significant difference in ABI between two groups
after adjusted analysis for glycemic control. One reason
of this finding may be the absence of ABI ≤ 0.9 in our
patients (The average of ABI within both good and poor
glycemic groups was 1.0).
One limitation of the study was that we did not assess
postprandial hyperglycemia and individual antioxidant
intake of the participants. In addition, due to the cross
sectional design of the study and small sample size, we
were not able to evaluate the influence of age, sex, dia-
betes duration, obesity, hypertension and hyperlipidemia
on oxidative stress and surrogate measures of subclinical
atherosclerosis comprehensively in these patients. Our
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results may be confounded as well by anti-diabetic, anti-
hypertensive and lipid lowering medications; almost all
of them have potent antioxidant effects and may have an
independent effect on TAS and surrogate SA markers
[48–50]. Complementary studies are needed in order to
confirm our findings.
Conclusions
Our observations are in favour of the hypothesis that
persistent hyperglycemia leads to decreased TAS levels
and worse CIMT which is more pronounced in diabetics
with poor glycemic control.
Considering the conflicting outcomes of different
studies it is suggested that further cohort studies with
larger number of patients are required to find out the
interrelationship and contribution of various risk factors
of atherosclerosis in diabetic patients. As expected the
blood pressure, lipid profile, weight, oxidative stress and
vascular stiffness in our patients with poor glycemic
control were worse than well controlled ones. Increased
CIMT, impaired ABI, and decreased TAS levels are con-
sidered to be the initial steps in cardiovascular complica-
tions of diabetes, which may be reversible. Thus in
diabetic patients we suggest assessment of TAS levels
concomitant with CIMT measurement for early initi-
ation of antioxidant therapy. In addition, it is necessary
to initiate primary and secondary preventive measures
such as including plenary life style modification and use
of lipid-lowering, antihypertensive and glucose-lowering
drugs to mitigate the devastating consequences of dia-
betes leading to CVD.
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